<?xml version='1.0' encoding='utf-8'?>
<document id="29493093"><sentence text="Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0." /><sentence text="The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas" /><sentence text="" /><sentence text="Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases" /><sentence text=" Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management" /><sentence text=" Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised"><entity charOffset="53-74" id="DDI-PubMed.29493093.s6.e0" text="tenofovir alafenamide" /><entity charOffset="98-127" id="DDI-PubMed.29493093.s6.e1" text="tenofovir disoproxil fumarate" /><pair ddi="false" e1="DDI-PubMed.29493093.s6.e0" e2="DDI-PubMed.29493093.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29493093.s6.e0" e2="DDI-PubMed.29493093.s6.e1" /></sentence><sentence text=" Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option"><entity charOffset="168-180" id="DDI-PubMed.29493093.s7.e0" text="dolutegravir" /><entity charOffset="181-192" id="DDI-PubMed.29493093.s7.e1" text="rilpivirine" /><pair ddi="false" e1="DDI-PubMed.29493093.s7.e0" e2="DDI-PubMed.29493093.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29493093.s7.e0" e2="DDI-PubMed.29493093.s7.e1" /></sentence><sentence text=" In contrast, dolutegravir monotherapy is not recommended"><entity charOffset="14-26" id="DDI-PubMed.29493093.s8.e0" text="dolutegravir" /></sentence><sentence text=" New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded" /><sentence text=" All drug-drug interaction tables have been updated and new tables are included" /><sentence text=" Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir"><entity charOffset="112-122" id="DDI-PubMed.29493093.s11.e0" text="sofosbuvir" /><entity charOffset="123-134" id="DDI-PubMed.29493093.s11.e1" text="velpatasvir" /><entity charOffset="135-147" id="DDI-PubMed.29493093.s11.e2" text="voxilaprevir" /><entity charOffset="152-163" id="DDI-PubMed.29493093.s11.e3" text="glecaprevir" /><entity charOffset="164-176" id="DDI-PubMed.29493093.s11.e4" text="pibrentasvir" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e0" e2="DDI-PubMed.29493093.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e0" e2="DDI-PubMed.29493093.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e0" e2="DDI-PubMed.29493093.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e0" e2="DDI-PubMed.29493093.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e0" e2="DDI-PubMed.29493093.s11.e4" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e1" e2="DDI-PubMed.29493093.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e1" e2="DDI-PubMed.29493093.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e1" e2="DDI-PubMed.29493093.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e1" e2="DDI-PubMed.29493093.s11.e4" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e2" e2="DDI-PubMed.29493093.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e2" e2="DDI-PubMed.29493093.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e2" e2="DDI-PubMed.29493093.s11.e4" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e3" e2="DDI-PubMed.29493093.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29493093.s11.e3" e2="DDI-PubMed.29493093.s11.e4" /></sentence><sentence text=" Recommendations on management of DAA failure and acute HCV infection have been expanded" /><sentence text=" For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10Â months" /><sentence text="" /><sentence text="Version 9" /><sentence text="0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages" /><sentence text="" /></document>